Stamulumab (MYO-029) – Kodiac biolabs

Our opinion on this compoundNiche research probe

37/100

First-in-class anti-myostatin antibody with clinical failure and residual selective probe value

Here’s the thing about stamulumab: it earns its place in the historical record as the first IgG1 antibody to selectively neutralize circulating myostatin (GDF-8), and the Wyeth program that produced it genuinely opened up an entire research program in muscle biology. But history and utility aren’t the same thing, and by now the compound has largely been superseded by what came after it.

The Phase 1/2 trial data is what it is. Across becker muscular dystrophy, facioscapulohumeral dystrophy, and limb-girdle dystrophy cohorts, stamulumab showed acceptable tolerability but produced muscle mass gains in the range of 0.5 to 1 percent. That’s not a rounding error on a real signal. That’s essentially not working. Wyeth (later Pfizer) chose not to advance it, which was the rational call. The compound’s mechanism is real, myostatin is a real negative regulator of skeletal muscle, but stamulumab itself didn’t translate the biology into a meaningful clinical effect.

What we find genuinely interesting is how the stamulumab failure shaped the next generation. Bimagrumab took a smarter angle, blocking ActRIIA/B at the receptor level rather than neutralizing circulating myostatin directly, and has achieved substantially larger lean mass effects in sarcopenia and metabolic disease trials. Domagrozumab and landogrozumab came later with refined anti-myostatin approaches. All of them owe something to stamulumab’s proof-of-concept work and failure map. That’s a real contribution to the field, even if it doesn’t push the compound’s score higher.

For a bench investigator, stamulumab still has some value as a selective myostatin neutralizer. If the research question is specifically about circulating GDF-8 and you want a well-characterized antibody with documented pharmacokinetics across multiple dose levels in actual humans, it’s a legitimate probe. Most research antibodies don’t have that. But we’d be honest: for most muscle biology programs, bimagrumab or more recent tools are going to be the better choice on nearly every dimension, including efficacy signal and mechanism breadth.

Thats the core issue here. The compound isn’t retracted, it isn’t disproven, the target is real. But it’s been outperformed on efficacy and superseded on mechanism design. It scores where it scores because it’s historically significant but no longer the leading edge of the question it helped define. For narrow, GDF-8-specific probe work, fine. For a general muscle biology or sarcopenia program, we’d look at the compounds stamulumab inspired before we’d reach for stamulumab itself.

Novelty: 35
Mechanism promise: 48
In-category differentiation: 22
Evidence quality: 50
Translational signal: 25
Research bench value: 45

Rationale Stamulumab was genuinely first-in-class for myostatin neutralization but Phase 1/2 data returned only 0.5-1% muscle mass gains across three dystrophy populations, deemed insufficient for advancement; it retains narrow probe utility for selective GDF-8 research but has been superseded by bimagrumab and later-generation agents on both mechanism design and clinical signal.

Anti-myostatin monoclonal antibody (research)

A humanized monoclonal antibody selective for myostatin (GDF-8); the first-in-class anti-myostatin antibody investigated for muscular dystrophy.

Abstract

Stamulumab (MYO-029; humanized IgG1 monoclonal antibody; molecular weight approximately 145 kDa) is a humanized monoclonal antibody selective for myostatin (GDF-8), developed at Wyeth (now Pfizer). The compound binds circulating myostatin in plasma, neutralizing the negative regulator of muscle growth. Phase 1/2 trials in adults with becker muscular dystrophy, facioscapulohumeral muscular dystrophy, and limb-girdle muscular dystrophy demonstrated tolerability but limited muscle mass increases (approximately 0.5 to 1 percent), which were considered insufficient to justify advancement. The compound is the first-in-class anti-myostatin antibody and informed subsequent development of bimagrumab (broader receptor target), domagrozumab, and landogrozumab. Used as a research compound for selective myostatin neutralization.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-360Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.